<DOC>
	<DOCNO>NCT02044380</DOCNO>
	<brief_summary>The main aim study evaluate safety tolerability afatinib patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) harbor Epidermal Growth Factor Receptor ( EGFR ) mutation ( ) never treat EGFR-Tyrosine Kinase Inhibitor ( TKI )</brief_summary>
	<brief_title>Afatinib Patients With Non Small Cell Lung Cancer ( NSCLC ) With Epidermal Growth Factor Receptor ( EGFR ) Mutations</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : 1 . Locally advanced metastatic Nonsmall Cell Lung Cancer ( NSCLC ) 2 . Epidermal Growth Factor Receptor ( EGFR ) mutationpositive result per institution 's test methodology 3 . Male female patient age &gt; =18 year 4 . Adequate organ function , define follow : 1 . Absolute neutrophil count ( ANC ) &gt; 1500/mm3 2 . Platelet count &gt; 75,000/mm3 3 . Serum creatinine &lt; 1.5 time upper limit ( institutional ) normal and/or creatinine clearance ( measure calculate ) &gt; 45ml/min 4 . Total bilirubin &lt; 1.5 time upper limit ( institutional ) normal 5 . Aspartate Amino Transferase ( AST ) Alanine Amino Transferase ( ALT ) &lt; three time upper limit ( institutional ) normal ( related liver metastasis &lt; five time ULN ) 5 . Eastern Cooperative Oncology Group ( ECOG ) score 02 6 . Written informed consent patient guardian prior admission trial consistent International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) guideline local law 7 . Recovery previous therapy relate toxicity &lt; =CTCAE Grade 1 study entry ( except stable sensory neuropathy &lt; =CTCAE Grade 2 alopecia ) Exclusion criterion : 1 . Prior treatment EGFR tyrosine kinase inhibitor ( TKI ) 2 . Hormonal anticancer treatment within 2 week prior start trial treatment ( continue use antiandrogens and/or gonadorelin analogue treatment prostate cancer permit ) 3 . Radiotherapy within 28 day prior drug administration , except follow : 1 . Palliative radiation organ chest may allow 2 week prior drug administration , 2 . Single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol 4 . Major surgery within 4 week start trial treatment schedule surgery project course trial 5 . Known hypersensitivity afatinib excipients 6 . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New York Heart Association ( NYHA ) classification 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior start trial treatment 7 . Women ChildBearing Potential ( WOCBP ) men able father child , unwilling use adequate contraception prior trial entry , duration trial participation least 2 week treatment end 8 . Childbearing potential : 1. nurse 2. pregnant 3. use acceptable method birth control , plan continue use method throughout trial and/or agree submit pregnancy test require protocol 9 . Any history concomitant condition , opinion investigator , would compromise patient ability comply trial interfere evaluation safety trial drug 10 . Previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure 11 . Requiring treatment prohibit concomitant medication stop duration trial participation 12 . Known preexist interstitial lung disease 13 . Presence poorly control gastrointestinal disorder could affect absorption trial drug ( e.g . Crohn 's disease , ulcerative colitis , malabsorption , Common Terminology Criteria grade =2 diarrhea aetiology ) base investigator assessment 14 . Active hepatitis B infection ( define presence Hepatitis B ( HepB ) sAg and/or HepB DNA ) , active Hepatitis C ( HEP C ) infection ( define presence Hep C RNA ) and/or know Human Immunodeficiency Virus ( HIV ) carrier 15 . Meningeal carcinomatosis 16 . Symptomatic brain metastasis ( patient asymptomatic brain metastasis , previously treat , eligible provide Stable Disease ( SD ) least 4 week stable dos corticosteroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>